In animal models of kidney IRI or cisplatin-induced AKI, PGC-1α decreased proportionally to the degree of kidney injury, while pharmacological activation or transgenic expression of PGC-1α improved mitochondrial function and renal injury [36, 37]. Here, PPARGC1A is linked to medical procedure.